Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun pharmacology A transition-state
analog inhibitor ofpurine nucleoside phosphorylase that is being developed to treatchronic lymphocytic leukemia .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word forodesine.
Examples
-
BioCryst is also conducting late-stage trials of a skin cancer treatment called forodesine, and a gout drug candidate designated BCX4208.
unknown title 2011
-
This decrease was driven by lower development costs associated with the peramivir and forodesine clinical programs following the completion of various clinical studies during 2010, partially offset by higher BCX4208 gout program development costs.
unknown title 2011
-
BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase PNP inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies.
unknown title 2011
-
These increases in R&D expenses were partially offset by a decrease of $2.1 million in development costs associated with the forodesine program.
BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update - Yahoo! Finance 2010
-
BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available
-
Additionally, forodesine HCl is being studied in a phase II trial with an oral formulation in Chronic Lymphocytic
THE MEDICAL NEWS 2010
-
The Company's product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP).
THE MEDICAL NEWS 2010
-
BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available
BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update - Yahoo! Finance 2010
-
BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).
-
BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).
Medindia Health News 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.